📊 CRBP Key Takeaways
Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) a Good Investment?
Corbus Pharmaceuticals faces critical operational challenges with only $2.8M revenue against -$24.3M operating losses and -$25.6M annual cash burn. At current burn rates, cash runway extends approximately 12 months, while deteriorating EPS (-60.3% YoY) and minimal revenue signal fundamental business failure or severe pipeline delays. The strong balance sheet provides temporary protection but cannot offset unsustainable core operations.
Corbus Pharmaceuticals shows very weak operating fundamentals, with minimal revenue relative to a very large operating loss and deeply negative margins, indicating the business is still far from self-funding. The balance sheet is a mitigating factor because liquidity is strong, leverage is effectively zero, and equity is substantial, but cash burn remains the central issue and growth quality cannot be considered strong until revenue becomes more durable and losses narrow.
Corbus Pharmaceuticals Holdings, Inc. Key Strengths (CRBP)
- Zero long-term debt with Debt/Equity ratio of 0.00x eliminates leverage risk
- Strong liquidity position with Current Ratio of 7.92x enabling operational continuity
- Substantial equity base of $126.3M providing financial cushion against imminent insolvency
- Strong liquidity with current and quick ratios of 8.07x
- Debt-free balance sheet with no long-term debt
- Large equity base relative to liabilities, providing financial flexibility
CRBP Stock Risks: Corbus Pharmaceuticals Holdings, Inc. Investment Risks
- Critically low revenue generation of $2.8M with no evidence of commercial product success
- Unsustainable annual cash burn of -$25.6M implying ~12-month cash runway at current trajectory
- Severe operating losses of -$24.3M on minimal revenue base with worsening diluted EPS (-60.3% YoY decline)
- Undefined gross profit structure (N/A reported) indicating either revenue volatility or production/supply constraints
- Extremely weak profitability, including -3094.3% operating margin and -2848.6% net margin
- Heavy cash burn, with operating cash flow and free cash flow around -$64.5M
- Very small revenue base of $2.76M, making the business highly dependent on external funding or future commercialization progress
Key Metrics to Watch
- Quarterly cash burn rate and revised cash runway estimates
- Sequential revenue trends and regulatory/commercialization milestones
- Operating expense trajectory and ability to reduce burn rate
- Clinical trial progress and pipeline advancement announcements
- Quarterly operating cash burn relative to cash balance
- Revenue scale-up and operating loss trend
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.92x current ratio provides a solid financial cushion.
CRBP Profit Margin, ROE & Profitability Analysis
CRBP vs Healthcare Sector: How Corbus Pharmaceuticals Holdings, Inc. Compares
How Corbus Pharmaceuticals Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Corbus Pharmaceuticals Holdings, Inc. Stock Overvalued? CRBP Valuation Analysis 2026
Based on fundamental analysis, Corbus Pharmaceuticals Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Corbus Pharmaceuticals Holdings, Inc. Balance Sheet: CRBP Debt, Cash & Liquidity
CRBP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Corbus Pharmaceuticals Holdings, Inc.'s revenue has declined by 98% over the 5-year period, indicating business contraction. The most recent EPS of $-3.68 indicates the company is currently unprofitable.
CRBP Revenue Growth, EPS Growth & YoY Performance
CRBP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2022 | N/A | -$2.2M | $-0.02 |
| Q2 2022 | $136.6K | -$13.2M | $-0.11 |
| Q1 2022 | N/A | -$9.4M | $-0.08 |
| Q3 2021 | $97.3K | -$2.2M | $-0.02 |
| Q2 2021 | $136.6K | -$17.1M | $-0.15 |
| Q1 2021 | $647.8K | -$16.1M | N/A |
| Q3 2020 | $1.2M | -$20.8M | N/A |
| Q2 2020 | $286.3K | $2.2M | $0.03 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Corbus Pharmaceuticals Holdings, Inc. Dividends, Buybacks & Capital Allocation
CRBP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Corbus Pharmaceuticals Holdings, Inc. (CIK: 0001595097)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRBP
What is the AI rating for CRBP?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRBP's key strengths?
Claude: Zero long-term debt with Debt/Equity ratio of 0.00x eliminates leverage risk. Strong liquidity position with Current Ratio of 7.92x enabling operational continuity. ChatGPT: Strong liquidity with current and quick ratios of 8.07x. Debt-free balance sheet with no long-term debt.
What are the risks of investing in CRBP?
Claude: Critically low revenue generation of $2.8M with no evidence of commercial product success. Unsustainable annual cash burn of -$25.6M implying ~12-month cash runway at current trajectory. ChatGPT: Extremely weak profitability, including -3094.3% operating margin and -2848.6% net margin. Heavy cash burn, with operating cash flow and free cash flow around -$64.5M.
What is CRBP's revenue and growth?
Corbus Pharmaceuticals Holdings, Inc. reported revenue of $2.8M.
Does CRBP pay dividends?
Corbus Pharmaceuticals Holdings, Inc. does not currently pay dividends.
Where can I find CRBP SEC filings?
Official SEC filings for Corbus Pharmaceuticals Holdings, Inc. (CIK: 0001595097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRBP's EPS?
Corbus Pharmaceuticals Holdings, Inc. has a diluted EPS of $-1.23.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRBP's fundamental grade?
Based on our AI fundamental analysis in June 2026, Corbus Pharmaceuticals Holdings, Inc. has a C grade with 85% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is CRBP stock overvalued or undervalued?
Valuation metrics for CRBP: ROE of -18.2% (sector avg: 15%), net margin of -833.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRBP's AI grade for 2026?
Our dual AI analysis gives Corbus Pharmaceuticals Holdings, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRBP's free cash flow?
Corbus Pharmaceuticals Holdings, Inc.'s operating cash flow is $-25.6M, with capital expenditures of $6.0K. FCF margin is -927.7%.
How does CRBP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -833.1% (avg: 12%), ROE -18.2% (avg: 15%), current ratio 7.92 (avg: 2).